Stay updated on Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page
- Check3 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.6%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check24 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check31 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check39 days agoChange DetectedThe page has removed a citation regarding the safety and efficacy of Pembrolizumab monotherapy in advanced gastric and gastroesophageal junction cancer, which was previously included.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.